MX2010006767A - Anticuerpos de virus de hepatitis c. - Google Patents

Anticuerpos de virus de hepatitis c.

Info

Publication number
MX2010006767A
MX2010006767A MX2010006767A MX2010006767A MX2010006767A MX 2010006767 A MX2010006767 A MX 2010006767A MX 2010006767 A MX2010006767 A MX 2010006767A MX 2010006767 A MX2010006767 A MX 2010006767A MX 2010006767 A MX2010006767 A MX 2010006767A
Authority
MX
Mexico
Prior art keywords
hepatitis
virus antibodies
virus
antibodies
fragments
Prior art date
Application number
MX2010006767A
Other languages
English (en)
Spanish (es)
Inventor
David J Matthews
David G Williams
Arvind Patel
Original Assignee
Medical Res Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council Technology filed Critical Medical Res Council Technology
Publication of MX2010006767A publication Critical patent/MX2010006767A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
MX2010006767A 2007-12-17 2008-12-17 Anticuerpos de virus de hepatitis c. MX2010006767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US606607P 2007-12-17 2007-12-17
PCT/IB2008/003952 WO2009081285A2 (en) 2007-12-17 2008-12-17 Hepatitis c virus antibodies

Publications (1)

Publication Number Publication Date
MX2010006767A true MX2010006767A (es) 2010-10-05

Family

ID=40801628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006767A MX2010006767A (es) 2007-12-17 2008-12-17 Anticuerpos de virus de hepatitis c.

Country Status (18)

Country Link
US (1) US9193781B2 (enExample)
EP (1) EP2231704B1 (enExample)
JP (1) JP5763344B2 (enExample)
KR (1) KR20100102163A (enExample)
CN (1) CN101939334B (enExample)
AR (1) AR072039A1 (enExample)
AU (1) AU2008341542B2 (enExample)
BR (1) BRPI0821252A2 (enExample)
CA (1) CA2708740C (enExample)
CL (1) CL2008003784A1 (enExample)
IL (1) IL205795A0 (enExample)
MX (1) MX2010006767A (enExample)
NZ (1) NZ585622A (enExample)
PE (1) PE20091109A1 (enExample)
RU (1) RU2462475C2 (enExample)
TW (1) TW200940090A (enExample)
WO (1) WO2009081285A2 (enExample)
ZA (1) ZA201003509B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12010987B2 (en) 2004-10-07 2024-06-18 Transmedics, Inc. Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status
NZ717789A (en) 2004-10-07 2017-09-29 Transmedics Inc Systems and methods for ex-vivo organ care
US9078428B2 (en) 2005-06-28 2015-07-14 Transmedics, Inc. Systems, methods, compositions and solutions for perfusing an organ
US9457179B2 (en) 2007-03-20 2016-10-04 Transmedics, Inc. Systems for monitoring and applying electrical currents in an organ perfusion system
US9462802B2 (en) 2008-01-31 2016-10-11 Transmedics, Inc. Systems and methods for ex vivo lung care
US20120027722A1 (en) * 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
ES2913104T3 (es) 2011-04-14 2022-05-31 Transmedics Inc Solución de cuidado de órganos para perfusión en máquina ex-vivo de pulmones de donantes
CN103649316B (zh) 2011-05-02 2017-07-28 约翰霍普金斯大学 合成的丙型肝炎基因组和制备及使用方法
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
EP2788704B1 (en) * 2011-12-09 2019-03-06 Applied Materials, Inc. Heat exchanger for cooling a heating tube and method thereof
ITFI20120122A1 (it) * 2012-06-15 2013-12-16 Kedrion S P A 50 Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso.
CN102928595A (zh) * 2012-10-12 2013-02-13 武汉康苑生物医药科技有限公司 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
RU2685185C2 (ru) 2013-09-19 2019-04-16 Новавакс, Инк. Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CA3185937A1 (en) 2014-06-02 2015-12-10 Transmedics, Inc. Ex vivo organ care system
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
EP4591895A3 (en) 2014-12-12 2025-11-12 TransMedics, Inc. Apparatus and method for organ perfusion
AU2016318622B2 (en) 2015-09-09 2021-05-20 Transmedics, Inc. Aortic cannula for ex vivo organ care system
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用
CN105177017B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r4-85及其应用
US10851160B2 (en) * 2016-03-22 2020-12-01 Institut National De La Sante Et De La Recherche Medicale Humanized anti-claudin-1 antibodies and uses thereof
BR112018074537B1 (pt) 2016-05-30 2023-04-11 Tevosol, Inc Método de ventilar um pulmão extraído
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659649B2 (en) * 1991-06-10 1995-05-25 Lucky Limited Hepatitis C diagnostics and vaccines
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用
ITRM20020049A1 (it) * 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
EP2481424A1 (en) * 2005-03-19 2012-08-01 Medical Research Council Improvements in or relating to treatment and prevention of hepatitis C viral infections

Also Published As

Publication number Publication date
US9193781B2 (en) 2015-11-24
KR20100102163A (ko) 2010-09-20
PE20091109A1 (es) 2009-08-12
EP2231704B1 (en) 2015-08-12
RU2010129429A (ru) 2012-01-27
TW200940090A (en) 2009-10-01
CA2708740C (en) 2017-07-18
AU2008341542A1 (en) 2009-07-02
WO2009081285A2 (en) 2009-07-02
AU2008341542B2 (en) 2014-12-04
CL2008003784A1 (es) 2009-08-14
NZ585622A (en) 2012-10-26
JP2011505867A (ja) 2011-03-03
CN101939334B (zh) 2015-01-14
IL205795A0 (en) 2010-11-30
AR072039A1 (es) 2010-08-04
JP5763344B2 (ja) 2015-08-12
HK1144440A1 (en) 2011-02-18
WO2009081285A3 (en) 2010-08-26
RU2462475C2 (ru) 2012-09-27
US20110002926A1 (en) 2011-01-06
CN101939334A (zh) 2011-01-05
ZA201003509B (en) 2011-12-28
EP2231704A2 (en) 2010-09-29
BRPI0821252A2 (pt) 2015-06-16
CA2708740A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
EA201492149A8 (ru) St2-антигенсвязывающие белки
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
IN2015DN01361A (enExample)
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
PH12013502205A1 (en) Antibodies to il-6 and their uses
ECSP12012272A (es) Proteínas que se unen al tnf-?
UY32752A (es) Polipéptidos y Métodos de Tratamiento
EA201291065A1 (ru) Антитела против vla-4
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
EA201590918A1 (ru) Антитела к bmp-6
UA107836C2 (uk) Метод лікування хвороби альцгеймера
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
EA200970834A1 (ru) Антитела к вирусу краснухи

Legal Events

Date Code Title Description
FA Abandonment or withdrawal